Home
News
- 1 MRNA stock price shows underperformance on the charts.
- 2 Buyers are trying to surpass the hurdle of $110 above the 50-day EMA.
Moderna Inc. (MRNA stock) is trading in a downtrend and retesting the neckline of $110 in the last sessions. Moreover, the price action favoring the bears and sellers persisted in adding short positions, resulting in a price decline for the past sessions. Furthermore, MRNA stock has now recovered the gains and showed a bounce from the support of $100 and retested the neckline of $110. However, the technicals suggest a further fall toward $100 in the following sessions.
MRNA stock price is now facing a 50-day EMA, a solid barrier to surpass for a short-term bounce. Moreover, the chart structure shows bearishness and underperformance for the past sessions. Bears look strong and dominate the battle, whereas bulls stay cautious and prevent the round mark of $100. A sharp bounce from the support of $100 means a strong demand zone was there, and sellers failed to fall below it.
At press time, MRNA stock price is trading at $112.56 with an intraday drop of 0.45%, showing bearishness on the charts. Moreover, the trading volume remained average at 3.787 Million, and the market cap is $42.84 Billion. However, Analysts maintained a buy and outperform rating with a yearly target price of $180.21, suggesting a strong growth outlook for the upcoming sessions.
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.
MRNA Stock Price Action Shows Bearishness On Daily Charts
On the daily charts, MRNA stock price action shows a downtrend and indicates bear dominance on the charts. The MRNA share price lost over 50% in the last six months, showing seller control for the past sessions. Furthermore, the price is trading below the 38.2% Fib level and is heading toward the 23.6% Fib level, indicating a decline on the charts. Moreover, the price is trading below the mid-Bollinger band, suggesting a further decline in the upcoming sessions.
The RSI curve stayed near neutrality and showed a bearish divergence, indicating a negative outlook for the upcoming sessions.
The MACD indicator shows a bullish crossover and formed green bars on the histogram, showing the exciting battle between bulls and bears.
Summary
Moderna stock price (MRNA) has underperformed for the past months and persists in declining. However, the price has taken support near the round mark of $100 and showed a bounce in the past week, whereas sellers are still trying for a further fall and trying to extend the downfall in the upcoming sessions.
Technical Levels
Support Levels: $100 and $85
Resistance Levels: $115 and $120
Disclaimer
The views and opinions stated by the author or any people named in this article are for informational purposes only, and they do not establish financial, investment, or other advice. Investing in or trading crypto or stock comes with a risk of financial loss.
Nancy J. Allen is a crypto enthusiast, with a major in macroeconomics and minor in business statistics. She believes that cryptocurrencies inspire people to be their own banks, and step aside from traditional monetary exchange systems. She is also intrigued by blockchain technology and its functioning. She frequently researches, and posts content on the top altcoins, their theoretical working principles and technical price predictions.
